3
Announcements
Trials
Browse
Landscape
Status
Completed
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
70
Observational
3
Expanded_access
1
Sponsor
Cancer Type
Genitourinary
3
Breast
1
Conditions
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Neuroendocrine Tumors
2
Neoplastic Cells, Circulating
1
Lymphangioleiomyomatosis
1
Carcinoma, Hepatocellular
1
Adenoma, Islet Cell
1
Interventions
Sunitinib
17
Sorafenib
16
pazopanib
7
cabozantinib
7
Axitinib
7
Blood Specimen Collection
6
Bevacizumab
6
avelumab
5
Immunohistochemistry
5
temsirolimus
4
pembrolizumab
3
Watchful Waiting
3
Specimen Handling
3
Immunotherapy
3
Gene Expression Profiling
3
Everolimus
3
Urine Specimen Collection
2
Nephrectomy
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
Flow Cytometry
2
Data Collection
2
Amplified Fragment Length Polymorphism Analysis
2
trastuzumab deruxtecan
1
lenvatinib
1
fluoroazomycin arabinoside
1
enfortumab vedotin
1
darolutamide
1
atezolizumab
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Observational
×
Carcinoma, Renal Cell
×
Everolimus
×
Clear all
NCT02184416
2026-02-27
ADONIS
Pfizer
Completed
554 enrolled
NCT02809404
2017-10-16
SPOT
Radboud University Medical Center
Completed
75 enrolled
NCT01390519
2016-01-13
OSAT
Novartis
Completed
30 enrolled